Effects of visual pathway lesions on the visual aura of migraine

The aim was to to determine if the visual aura of migraine is altered by disease of the afferent visual pathways and if visual aura changes are associated with pre- or postgeniculate lesions. Functional neuroimaging during migraine demonstrates primary visual/extrastriate cortex as an anatomical substrate of visual aura. Neuro-ophthalmological records (including kinetic and static perimetry) of 25 patients with visual loss and typical aura with or without migraine headache were reviewed. Twenty-five patients (16 women, nine men) (mean age 59.8 years) with typical aura had visual loss from pregeniculate (72%) or postgeniculate lesions (28%). Eight patients (four postgeniculate cerebrovascular accidents or arteriovenous malformations, two lifelong optic neuropathy/retinopathy, one childhood ocular trauma, one anisometropic amblyopia) reported absence or alteration of visual aura. Postgeniculate lesions were significantly associated ( P  = 0.017) with visual aura changes. The association of postgeniculate lesions with altered auras points to a postgeniculate effect on aura appearance (consistent with functional neuroimaging findings). Although statistically significant, this series' association of postgeniculate disease and aura changes is even more robust ( P  = 0.0002) when structural changes of ocular dominance columns are posited in three patients with optic neuropathy, retinopathy and keratopathy of congenital or childhood origin.     

露蕊乌头的二萜生物碱

从露蕊乌头(Aconitum gymnandrum Maxim)中分离到11个二萜生物碱,利用光谱方法确定结构,证明其中一个为新生物碱,命名为露乌定,其余10个分别鉴定为14-乙酰基-8-O-甲基-塔拉胺(tal-atisamine,Ⅱ)、acoforine(Ⅲ)、非洲防己碱(columbidine,Ⅳ)、乌头碱(aconitine,Ⅴ)、ranaeonitine(Ⅵ)、塔拉定(talatizidine,Ⅶ)、异塔拉定(isotalatizidine.Ⅷ)、露乌碱(gymanaconitine,Ⅸ)、塔拉胺(talatisamine,Ⅹ)和阿替辛盐酸盐(atisine.HCl)。其中碱Ⅱ为首次在自然界中发现,碱Ⅲ～Ⅶ为首次从该植物中分离得到。     

Uterine sarcomas: a clinicopathologic study

A series of 48 cases with initial diagnosis of uterine sarcoma was reviewed to evaluate the validity of histologic criteria. The influence of pathologic and clinical prognostic factors and treatment modalities were examinated. The 32 patients included in this retrospective study after pathologic review had 5-year overall survival rate of 13.1%. Surgical pathological staging was demonstrated to be a significant prognostic factor, since patients with FIGO stage I-II disease had 33.5% actuarial survival rate whereas no patient with stage III-IV disease was alive at 37 months. Histological type, age and menopausal status did not significantly influence survival. Presence of heterologous elements and lymphovascular invasion were associated with a poor prognosis in the subgroup of patients with mixed mesodermal tumors. Median survival for patients receiving adjuvant treatment was 25 months compared to 19 months for those undergoing no adjuvant therapy.     

Cancer in women.

Incidence, mortality and survival trends for the most frequent cancers affecting women are presented on a worldwide basis. Data sources are represented by several different cancer databases, as no single world cancer database covers these epidemiological measures. Monitoring cancer incidence, mortality and survival are fundamental indicators which allow estimates and predictions of geographical and temporal changes of these diseases, enabling the design and set-up of adequate cancer control activities and national health programs. The observed differences in cancer incidence, mortality and survival in more developed countries compared with less developed countries (as defined by WHO) are mainly due to different individual and social risk factors between the two geo-political areas. For some cancers, advancements in screening, diagnosis and treatment in the more developed areas were the most effective factors in reducing incidence and mortality as well as prolonging survival. These effects were not detected in the less developed areas because of the limited access to primary and specialist care.     

Investigation of the Ovarian and Prostate Cancer Peptidome for Candidate Early Detection Markers Using a Novel Nanoparticle Biomarker Capture Technology

Current efforts to identify protein biomarkers of disease use mainly mass spectrometry (MS) to analyze tissue and blood specimens. The low-molecular-weight “peptidome” is an attractive information archive because of the facile nature by which the low-molecular-weight information freely crosses the endothelial cell barrier of the vasculature, which provides opportunity to measure disease microenvironment-associated protein analytes secreted or shed into the extracellular interstitium and from there into the circulation. However, identifying useful protein biomarkers (peptidomic or not) which could be useful to detect early detection/monitoring of disease, toxicity, doping, or drug abuse has been severely hampered because even the most sophisticated, high-resolution MS technologies have lower sensitivities than those of the immunoassays technologies now routinely used in clinical practice. Identification of novel low abundance biomarkers that are indicative of early-stage events that likely exist in the sub-nanogram per milliliter concentration range of known markers, such as prostate-specific antigen, cannot be readily detected by current MS technologies. We have developed a new nanoparticle technology that can, in one step, capture, concentrate, and separate the peptidome from high-abundance blood proteins. Herein, we describe an initial pilot study whereby the peptidome content of ovarian and prostate cancer patients is investigated with this method. Differentially abundant candidate peptidome biomarkers that appear to be specific for early-stage ovarian and prostate cancer have been identified and reveal the potential utility for this new methodology     

部分睡眠剥夺对大鼠糖代谢的影响

1材料和方法 1.1材料血糖仪(Accu-CHEK Softclix(R)2 LANCING DEVICE)及大平台水箱由第四军医大学教学实验中心提供.小平台水箱由第四军医大学航天航空医学系心理教研室提供.INS试剂盒,购自中国人民解放军总医院科技开发中心放免研究所.